Licensing is the purest revenue in commerce. Someone else deploys the capital, hires the staff, and carries the inventory. The licensor collects a contractual percentage for the use of an intangible: a brand, a patent, a recipe, a standard. Gross margin approaches 100%. The costs are enforcement, quality control and partner support. Capital intensity approaches zero. ROIC therefore approaches infinity and FCF conversion approaches 100%. The catch is on the other side of the same coin. The licensor's revenue is a derivative of partner health and contract terms. You give up control of execution and keep a claim on its outcome.
Licensing business model examples: McDonald's and Domino's
McDonald's (US). In illustrative ~2024 figures, ~95% of ~43,000 restaurants are franchised. Systemwide sales are ~$130bn, yet McDonald's own revenue is only ~$26bn. Of that, ~$16bn is franchise royalties (~4 to 5% of franchisee sales) plus rent, because McDonald's owns much of the land. It's a real-estate annuity welded to a brand royalty, and it earns ~82 to 85% segment margins. Company-operated stores contribute revenue at ~15% margins. Operating margin is ~45%. Notice the rhyme with GMV: systemwide sales : revenue :: GMV : take rate. The same rule applies, so never compare a franchisor's revenue to an operator's.
Advertisement
Domino's two ways (US and India). Domino's Inc. (US) has revenue of ~$4.7bn. Its largest line is low-margin supply-chain sales to franchisees, ~$2.9bn at ~11%. The profit engine is royalties, on global retail sales of ~$19bn × ~3 to 5.5%, at ~90% margins. It's one more case of the biggest line not being where the profit is. Jubilant FoodWorks (India) is the other side of the same contract. It's a listed licensee, paying ~3.3 to 3.5% of sales as royalty for the Domino's brand in India (see its AR). India's listed universe is full of licensees. Page Industries holds Jockey, licensed to 2040, at a royalty of ~5%. Devyani and Sapphire run Yum brands. And nearly every multinational's listed subsidiary pays its parent a royalty. HUL's royalty stepped up toward ~3.45% of turnover over 2023 to 25, and Tata companies pay ~0.25% brand fees to Tata Sons. Read those lines with a governance eye, because a royalty is a pre-dividend skim approved by the payer's board.
How does pharma out-licensing work?
Pharma out-licensing (India's export version). Memorise the structure: upfront (certain) + development/regulatory/sales milestones (contingent) + tiered royalties on net sales (the annuity). Here's a real recent shape. Glenmark's innovation arm IGI licensed its oncology asset ISB 2001 to AbbVie in 2024 for a ~$700m upfront, up to ~$1.2bn of milestones, plus tiered double-digit royalties (announced terms). Natco's US model applies licensing economics to Para-IV risk. Natco develops and litigates the generic, lets a partner market it, and splits the profits. Its Copaxone partnership with Mylan worked that way, and so did its partnered generic-Revlimid launch, per its AR. To handle these, value the certain pieces as cash flows and the contingent pieces as probability-weighted scenarios (Practice P7 does the maths). A milestone year is a windfall, so never annualise it as if it recurred.
What should you check in the filings?
What to check in filings: the royalty rate and the base it's charged on (net sales? systemwide?). Contract tenor and renewal terms. Partner concentration and health. Minimum guarantees. For Indian licensees, also track the royalty-rate trend as a governance signal.